Cantourage Group Se · XETR:HIGH
Cantourage — Investor Presentation (September 2026)
31 slides from Cantourage's investor presentation, September 2026
Slide 1: Cantourage company presentation
September 2026 Cantourage company presentation
Slide 2: Europe's Leading Medical Cannabis Platform – Investment Highlights
Europe’s Leading MEDICAL CANNABIS PLATFORM Investment Highlights One of the very few, Continued Scalable, asset -light Strong market Diversified product pan -European profitable growth and (working) position in portfolio catering medical cannabis in highly regulated capital -efficient Germany, UK, t
Slide 3: Relevant across multiple indications
Relevant across multiple indications Growing use cases drive adoption among doctors and patients alike Neurology and mental health conditions (e.g. epilepsy, MS, PTSD, migraines) Cardiovascular function Autoimmune conditions Respiratory conditions Nausea, appetite disorders, pain Chronic digestive c
Slide 4: Pan-European Player
Pan - European Player Revenue mix increasingly diversified – international markets contribute 54% of Q2 revenue , up from 16% Cantourage mainly operates 10% in five countries UK Poland and considers Germany France, Italy & Switzerland Spain to be Revenvue 46% Austria promising markets mix France for
Slide 5: Germany
Germany 84,0mn +17mn +500k <3,0% Population Potential patients Medical cannabis patients Penetration of adressable pool Market highlights Key growth drivers Regulatory environment ▪ Sustained , albeit slowing market ▪ Simplified prescribing process ▪ Medical cannabis legal since March 2017 momentum
Slide 6: GER | GKV Reform
GER | GKV Reform The legislative changes primarily affect reimbursement pathways rather than patient access . Key provisions affecting medical cannabis Management assessment ▪ Medical cannabis flowers will generally no longer be ▪ >90% of Cantourage's flower sales are estimated to eligible for statu
Slide 7: Cantourage Brand gramz.
Cantourage Brand " gramz ." Leverage data / insights for successful launches Leveraging market insights from Sales and telemedicine offerings to systematically introduce highly sought after products Expand sourcing opportunites P roviding new financial model to new and existing growers unlocks addit
Slide 8: United Kingdom
United Kingdom 69,5mn +5mn +100k <1,0% Population Potential patients Medical cannabis patients Penetration of addressable pool Market highlights Key growth drivers Regulatory environment ▪ Largest addressable market in ▪ High prevalence of chronic pain and ▪ Medical cannabis has been legal since Eur
Slide 9: Poland
Poland 37,5mn 6- 8mn +300k <5% Population Potential patients medical cannabis patients Penetration of addressable pool Market highlights Key growth drivers Regulatory environment ▪ One of the fastest -growing medical ▪ High unmet medical needs ▪ Medical cannabis has been legal since 2017 cannabis ma
Slide 10: Can° Opportunity
Can ° Opportunity Population Patient potential Cannabis patients Market penetration (in mn) (in mn) (in mn) (in %) GER 84,0 +17 +0,8 <5,0 UK 69,5 +5 +0,1 <0,5 POL 37,5 +6 +0,3 <5,0 Can ° 191 +28 +1,2 <5 World Over 150 million people Around 60 million people More than 100 million people suffer from s
Slide 11: Growing markets
Growing markets European medical cannabis markets are growing rapidly Medical cannabis verifiably Imports of medical cannabis in Germany improves the quality of life (in tons) 60 Over 150 million people 50 suffer from sleep disorders 40 30 Around 60 million people struggle with anxiety disorders 20
Slide 12: Cantourage is positioned to capture significant market potential
Across Germany, the UK and Poland Cantourage is positioned to capture significant market potential – with a strategy focused on access , innovation and growth . 12
Slide 13: Two core challenges
Two core challenges Two core challenges leading to market fragmentation and inefficiency Shortage of consistent supply & Lack of doctors & pharmacies 1 innovative products in the European medical cannabis market 2 limiting access for patients Many excellent cannabis growers worldwide Despite growing
Slide 14: Global supply chain
Global supply chain Cantourage may bring any legal cultivator into its EU targets markets within three to six months 01 02 03 04 Cantourage + growers Cantourage Cantourage + partners Cantourage Certify selected Import raw Manufacture Distribute & sell growers materials into pharmaceuticals to pharma
Slide 15: Cantourage platform enabling growers to supply European markets
Cantourage platform enabling growers to quickly & efficiently supply the European medical cannabis markets 15
Slide 16: Access solution
Access solution Cantourage addresses these two core challenges with its unique operating model How to get a prescription for medical cannabis? How to find a pharmacy dispensing medical cannabis? 16
Slide 17: Access solution – telemedicine platforms
Access solution Cantourage addresses these two core challenges with its unique operating model Cantourage’s telemedicine platforms in Germany & UK offering safe & efficient start of therapy Online registration Initial consultation Prescription Medicine Patients complete the The first appointment The
Slide 18: Cantourage's telemedicine platforms provide safe & efficient access
Cantourage’s telemedicine platforms provide safe & efficient access for patients to medical cannabis 18
Slide 19: Asset-light operating model
Asset - light OPERATING MODEL Unique asset -light operating model enabling further profitable growth Growing Production Wholesale Tele - Medicine No. of groups Sourcing from selected growers around the world + + + + + + 1 and direct connection to pharmacies & patients Vertically integrated Own culti
Slide 20: Diverse portfolio of products
Diverse portfolio OF PRODUCTS S uccessful in key market segments Dried flowers Cannabidiol API Dronabinol API Dronabinol Solution 20
Slide 21: Flower portfolio
Flower portfolio Global network enables flexible responses to patient needs Multi -brand strategy enables a broad offering from “value” to “premium” Revenue -sharing model with growers Pharmacies and patients particularly appreciate the wide range of products 21
Slide 22: Cantourage has diversified its business from the start
Cantourage has diversified its business right from the start – with regard to products & target markets 22
Slide 23: The flexible & agile operating model
The flexible & agile operating model allows for swift reactions to changing market demands all over Europe 23
Slide 24: Core KPIs
Core KPIs Flower sales (in kgs) SKUs (#) 20000 > 18000 As of end of 2025 15000 10000 5000 > 2000 > 8000 200 + 0 2023 2024 2025 In 2025, Cantourage supplied medical cannabis to over 100,000 patients on a monthly basis 24
Slide 25: Strong performance
Strong performance 2019 2020 2021 2022 2023 2024 2025 92,8 Revenue EBITDA 75 7,5 5,7 50,9 50 5 3,5 23,6 25 2,5 14,1 5,2 0 0,5 0 0 -0,2 -0,3 -0,6 -0,8 -2,4 25
Slide 26: Strategic shift delivers
Strategic shift delivers Highligts Q2 2026 21.8mn 13.1 % Gramz. Q2 revenue reflects EBITDA rises 45% Cantourage brand strategic decision to EUR 2.9 million strengthens to focus on higher - despite lower differentiation, margin business in revenue – EBITDA margin potential and Germany margin nearly l
Slide 27: Strong Margin Expansion
Strong Margin Expansion ▪ Revenue of EUR 21.8m ( -22%) – reflecting the deliberate focus on higher -margin premium products in Germany ▪ EBITDA increases to EUR 2.9m (+45%) EBITDA margin rises to 13.1% from 7.0% in the prior -year quarter ▪ Gross margin improves to 36.4% from 28.5%, clearly validati
Slide 28: Financial Flexibility
Financial Flexibility ▪ Equity ratio of 71.3% underlines the strong capital base ▪ Net cash position increases to EUR 9.3m ▪ Strong financial position supports the consistent execution of the growth strategy Equity ratio Net cash position (in %) (in EUR mill.) 100 95 9,3 90 81,2 10 8,8 85 80 71,8 75
Slide 29: 2026 and beyond
2026 and beyond Cantourage will continue its profitable growth – and further diversify its product and service portfolio Based on the business performance to date and the outlook for the remainder of FY2026, the Management Board expects Group revenue of EUR 85 – 95 million and consolidated Adjusted
Slide 30: Market Outlook
Market Outlook Europe is expected The trend toward Demand is rising The opening of a to become the legalizing medical rapidly, driven by recreational market world's largest cannabis is gaining an aging population would present market for medical momentum considerable upside cannabis potential 30
Slide 31: Cantourage Group SE
Cantourage Group SE Feurigstr. 54, 10827 Berlin +49 (0)30 4701 350 – 50 www.cantourage.com
Cantourage Group — Investor Presentation (September 2026) on 6ix